We enable organizations to experiment on thousands of lab-grown human tissues and dissect biological complexity with superhuman AI.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Total raised: $82M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 25.10.2023 | MBX Capita... | mbxcapital... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.05.2025 | Series A | $40M | - |
| 20.12.2023 | Seed | $38M | - |
| 31.03.2021 | Seed | $4M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.12.2025 | Why MBX Capital is Betting $100M on the Link Between Industrial Toxins and Chronic Disease | What You Should Know: – MBX Capital has secured over $100M in capital commitments to invest in early-stage biotech and health tech companies, specifically focusing on “deep health” solutions that address diseases linked to environmental tox... |
| 30.05.2025 | Vivodyne Secures $40M Series A to Scale AI-Powered Human Tissue Testing | What You Should Know: – Vivodyne, a company pioneering an exclusively human-focused preclinical process, today announced it has raised $40M in new Series A funding led by Khosla Ventures, with participation from new investors Lingotto Inves... |
| 29.05.2025 | Vivodyne Raises $40M Series A Financing | SAN FRANCISCO, CA, Vivodyne has raised $40 million in new Series A financing. >> Click here for more funding data on Vivodyne >> To export Vivodyne funding data to PDF and Excel, click here By shifting from animals to an exclus... |
| 29.05.2025 | Vivodyne Raises $40M in Series A Funding | Vivodyne, a San Francisco, CA-based company developing drug testing on lab-grown 3D human tissues, raised $40M in Series A funding. The round was led by Khosla Ventures, with participation from new investors Lingotto Investment Management, ... |
| 20.12.2023 | Philly Money Moves: Biotech firm Vivodyne raised $38M for lab-grown organ development | Money Moves is a column where we chart the raises, mergers and other funding news of tech companies across the region on the third Wednesday of the month. Have a tip? Email us at philly@technical.ly. Update: Mention of PolicyMap's Series A ... |
| 30.11.2023 | Vivodyne Secures $38M for AI-Powered Drug Discovery Platform | Vivodyne started as an idea between Co-Founders Andrei Georgescu (left), now Vivodyne’s CEO, and UPenn Professor Dan Huh (right), now Vivodyne’s CSO, while Andrei performed his Ph.D. graduate studies in Huh’s bioengineering research lab. Ph... |
| 24.11.2023 | USA-based Vivodyne raises USD 38 million in seed funding | Philadelphia, USA-based biotech company discovering and developing more effective drugs by testing them on lab-grown human organs, Vivodyne raised USD 38 million in seed funding. The round took place on November 22, 2023. Khosla Ventures le... |
| 22.11.2023 | Vivodyne launches with $38M to create lab-grown human organs | Photo courtesy of Vivodyne |
| 22.11.2023 | Vivodyne Raises $38M in Seed Financing | Susan Billings (right), Vivodyne’s Chief Commercial Officer, and Andrei Georgescu stand in Vivodyne’s Philadelphia laboratory, where the company accelerates the development of cures to human diseases by using their robotic platforms (left) ... |
| 19.04.2021 | This Penn-founded biotech company specializing in human ‘organs on chip’ raised $4M | A University of Pennsylvania-founded biotech company that helps scientists test drugs and therapeutics has raised $4 million in order to more widely adopt their platform that embraces “organs on chip” technology. Research into potential dru... |
Show more